Evaluation of Genetic Factors for Warfarin Dose Prediction (Clin Med Res 2007;5:8–16. doi:10.3121/cmr.2007.724)
Michael D. Caldwell, MD, PhD; Richard L. Berg, MS; Kai Qi Zhang, BS; Ingrid Glurich, PhD; John R. Schmelzer, PhD; Steven H. Yale, MD; Humberto J. Vidaillet, MD; and James K. Burmester, PhD†
The original article to which this correction refers was published in the March 2007 issue of Clinical Medicine & Research (Clin Med Res 2007;5:8–16. doi:10.3121/cmr.2007.724).
The authors reported the groups were incorrectly labeled in the originally published version of Figure 1A⇓. The correct group labels are (left to right) *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, *3/*3. These are the same groups that are further partitioned in Figure 1B⇓. A corrected figure is provided here (see corrected Figure 1A⇓).
† Address correspondence to: James K. Burmester, PhD; Center for Human Genetics, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI 54449. Telephone: 715-389-4368; Fax: 715-389-3808; Email:[email protected].
![Stable coumadin dose by genotype. Distribution of weekly stabilizing warfarin dose in relation to (A) CYP2C9 and (B) CYP2C9 and VKORC1 genotypes. The CYP2C9 genotype is labeled as *1/*1, *1/*2, *1/*3, *2/*2, *2/*3 and *3/*3. For (B), within each CYP2C9 genotype, the VKORC1 genotype is shown as GG, GC or CC. [see original Figure 1 to view panel B].](https://www.clinmedres.org/content/clinmedres/5/2/142/F1.large.jpg)
Stable coumadin dose by genotype. Distribution of weekly stabilizing warfarin dose in relation to (A) CYP2C9 and (B) CYP2C9 and VKORC1 genotypes. The CYP2C9 genotype is labeled as *1/*1, *1/*2, *1/*3, *2/*2, *2/*3 and *3/*3. For (B), within each CYP2C9 genotype, the VKORC1 genotype is shown as GG, GC or CC. [see original Figure 1 to view panel B].
